Mirna Therapeutics (NASDAQ:SYBX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday, November 22nd.
According to Zacks, “Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company’s pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts. “
SYBX has been the topic of several other research reports. ValuEngine lowered shares of Mirna Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Leerink Swann began coverage on shares of Mirna Therapeutics in a research note on Tuesday, September 19th. They set an “outperform” rating and a $25.00 price target for the company. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company’s stock. Mirna Therapeutics presently has an average rating of “Hold” and an average price target of $19.67.
Mirna Therapeutics (NASDAQ:SYBX) traded up $0.49 during mid-day trading on Wednesday, hitting $10.59. 101,991 shares of the stock were exchanged, compared to its average volume of 14,322. Mirna Therapeutics has a one year low of $8.76 and a one year high of $23.00.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.thelincolnianonline.com/2017/12/07/zacks-investment-research-downgrades-mirna-therapeutics-inc-sybx-to-sell-updated-updated.html.
About Mirna Therapeutics
Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.